Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe, Frances A. Collichio

ABSTRACT

BACKGROUND: With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments modalities is unknown. Combining or sequencing these agents could potentially result in unique toxicities. Cutaneous adverse events (CAE) after sequential exposure to these agents represents one toxicity that needs further description. METHODS: After retrospectively reviewing charts of patients from 2015 to 2018, we identified six patients who experienced CAEs after recent exposure to sequential immunotherapy and TT or vice versa for the treatment for metastatic melanoma at the University of North Carolina, Chapel Hill. Skin biopsies were available in five patients. RESULTS: Five patients received TT after immunotherapy, and one patient received immunotherapy after TT. TT consisted of vemurafenib/cobimetinib (V/C) in five patients with four patients starting V/C immediately before manifesting with a CAE. In patients receiving V/C after immunotherapy, the median time from beginning V/C to development of CAE was 14.5 days. The clinical presentation of diffuse morbilliform rash, fevers, hypotension, and end-organ damage raised concern for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Histopathological features of lympho-eosinophilic infiltrate were supportive of a drug eruption. Immunotherapy or TT were re-initiated in five patients within 1-8 weeks after resolution of the index CAE. This resulted in two patients re-experiencing the CAE. Both of these patients were off prednisone at the time of therapy re-initiation, whereas none of the patients who were restarted on targeted therapy with a steroid overlap had a rash recurrence. CONCLUSIONS: Sequential treatment using immunotherapy and TT, especially the sequence of V/C after immunotherapy appears to be the most common trigger for CAE with a median time to onset of approximately 2 weeks. Although the clinical presentation of these CAEs can be dramatic, they respond well to prednisone therapy. This unique presentation suggests that it may be reasonably safe to re-challenge certain patients with a steroid overlap after rash resolution. More... »

PAGES

4

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-018-0475-y

DOI

http://dx.doi.org/10.1186/s40425-018-0475-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111265578

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30621779


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "East Carolina University", 
          "id": "https://www.grid.ac/institutes/grid.255364.3", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, Vidant Cancer Center at East Carolina University, 600 Moye Blvd, 27834, Greenville, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naqash", 
        "givenName": "Abdul Rafeh", 
        "id": "sg:person.01165122667.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165122667.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina System", 
          "id": "https://www.grid.ac/institutes/grid.410711.2", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "File", 
        "givenName": "Danielle M.", 
        "id": "sg:person.016642556614.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016642556614.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina System", 
          "id": "https://www.grid.ac/institutes/grid.410711.2", 
          "name": [
            "Department of Dermatology, University of North Carolina, 27516, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ziemer", 
        "givenName": "Carolyn M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Whang", 
        "givenName": "Young E.", 
        "id": "sg:person.01006050445.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006050445.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "UNC Health Care, The University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landman", 
        "givenName": "Paula", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Department of Dermatology, Pathology and Laboratory Medicine, University of North Carolina School of Medicine, 250 Bell Tower Drive CB#7287, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Googe", 
        "givenName": "Paul B.", 
        "id": "sg:person.0670500635.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670500635.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Department of Medicine, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collichio", 
        "givenName": "Frances A.", 
        "id": "sg:person.011104144247.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104144247.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-13-0092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008089107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1114329", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014731818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1346-8138.13489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031769697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.52.1377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032160428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2133.2006.07704.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033804905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13892", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035467171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13892", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035467171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.aaa4691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043215332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-13-0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044941438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834015616934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834015616934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djv414", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079221501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2017.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084511385", 
          "https://doi.org/10.1038/nrclinonc.2017.43"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085285234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-017-2993-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085391334", 
          "https://doi.org/10.1007/s00277-017-2993-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-017-2993-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085391334", 
          "https://doi.org/10.1007/s00277-017-2993-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/14737140.2017.1341315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085978821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx325", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086385919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105411325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105411325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105411325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.3014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106841551"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments modalities is unknown. Combining or sequencing these agents could potentially result in unique toxicities. Cutaneous adverse events (CAE) after sequential exposure to these agents represents one toxicity that needs further description.\nMETHODS: After retrospectively reviewing charts of patients from 2015 to 2018, we identified six patients who experienced CAEs after recent exposure to sequential immunotherapy and TT or vice versa for the treatment for metastatic melanoma at the University of North Carolina, Chapel Hill. Skin biopsies were available in five patients.\nRESULTS: Five patients received TT after immunotherapy, and one patient received immunotherapy after TT. TT consisted of vemurafenib/cobimetinib (V/C) in five patients with four patients starting V/C immediately before manifesting with a CAE. In patients receiving V/C after immunotherapy, the median time from beginning V/C to development of CAE was 14.5\u2009days. The clinical presentation of diffuse morbilliform rash, fevers, hypotension, and end-organ damage raised concern for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Histopathological features of lympho-eosinophilic infiltrate were supportive of a drug eruption. Immunotherapy or TT were re-initiated in five patients within 1-8\u2009weeks after resolution of the index CAE. This resulted in two patients re-experiencing the CAE. Both of these patients were off prednisone at the time of therapy re-initiation, whereas none of the patients who were restarted on targeted therapy with a steroid overlap had a rash recurrence.\nCONCLUSIONS: Sequential treatment using immunotherapy and TT, especially the sequence of V/C after immunotherapy appears to be the most common trigger for CAE with a median time to onset of approximately 2 weeks. Although the clinical presentation of these CAEs can be dramatic, they respond well to prednisone therapy. This unique presentation suggests that it may be reasonably safe to re-challenge certain patients with a steroid overlap after rash resolution.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-018-0475-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series", 
    "pagination": "4", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "aad389d22b6c4a07def7164f5be81980c4a197d4ff07dc25d6fcd007ea71e5cf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30621779"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-018-0475-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111265578"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-018-0475-y", 
      "https://app.dimensions.ai/details/publication/pub.1111265578"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000314_0000000314/records_55829_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-018-0475-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0475-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0475-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0475-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0475-y'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-018-0475-y schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N4878f90b5e01444d93c57767190079de
4 schema:citation sg:pub.10.1007/s00277-017-2993-y
5 sg:pub.10.1038/nrclinonc.2017.43
6 https://doi.org/10.1056/nejmc1114329
7 https://doi.org/10.1080/14737140.2017.1341315
8 https://doi.org/10.1093/annonc/mdx187
9 https://doi.org/10.1093/annonc/mdx325
10 https://doi.org/10.1093/jnci/djv414
11 https://doi.org/10.1097/cmr.0000000000000472
12 https://doi.org/10.1111/1346-8138.13489
13 https://doi.org/10.1111/j.1365-2133.2006.07704.x
14 https://doi.org/10.1111/jdv.13892
15 https://doi.org/10.1126/scitranslmed.aaa4691
16 https://doi.org/10.1158/2326-6066.cir-13-0092
17 https://doi.org/10.1158/2326-6066.cir-13-0215
18 https://doi.org/10.1177/1758834015616934
19 https://doi.org/10.1200/jco.2013.52.1377
20 https://doi.org/10.1200/jco.2016.34.15_suppl.3014
21 schema:datePublished 2019-12
22 schema:datePublishedReg 2019-12-01
23 schema:description BACKGROUND: With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments modalities is unknown. Combining or sequencing these agents could potentially result in unique toxicities. Cutaneous adverse events (CAE) after sequential exposure to these agents represents one toxicity that needs further description. METHODS: After retrospectively reviewing charts of patients from 2015 to 2018, we identified six patients who experienced CAEs after recent exposure to sequential immunotherapy and TT or vice versa for the treatment for metastatic melanoma at the University of North Carolina, Chapel Hill. Skin biopsies were available in five patients. RESULTS: Five patients received TT after immunotherapy, and one patient received immunotherapy after TT. TT consisted of vemurafenib/cobimetinib (V/C) in five patients with four patients starting V/C immediately before manifesting with a CAE. In patients receiving V/C after immunotherapy, the median time from beginning V/C to development of CAE was 14.5 days. The clinical presentation of diffuse morbilliform rash, fevers, hypotension, and end-organ damage raised concern for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Histopathological features of lympho-eosinophilic infiltrate were supportive of a drug eruption. Immunotherapy or TT were re-initiated in five patients within 1-8 weeks after resolution of the index CAE. This resulted in two patients re-experiencing the CAE. Both of these patients were off prednisone at the time of therapy re-initiation, whereas none of the patients who were restarted on targeted therapy with a steroid overlap had a rash recurrence. CONCLUSIONS: Sequential treatment using immunotherapy and TT, especially the sequence of V/C after immunotherapy appears to be the most common trigger for CAE with a median time to onset of approximately 2 weeks. Although the clinical presentation of these CAEs can be dramatic, they respond well to prednisone therapy. This unique presentation suggests that it may be reasonably safe to re-challenge certain patients with a steroid overlap after rash resolution.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N194c0ac09f49416f9d5258069f2ccac2
28 N249f80e26db544d1ad2205c483013c30
29 sg:journal.1049249
30 schema:name Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
31 schema:pagination 4
32 schema:productId N2b6ab171281c431a90cc35a18585c579
33 N38aff7d9536f4cbc9f11bbde3d7ea33e
34 N521c8c77ec2a4b3190b6c5e3b284b058
35 N8dc1fbf03bac40708d68b9f906a17552
36 Na3ceb708bf6b49228afb509a882bb812
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111265578
38 https://doi.org/10.1186/s40425-018-0475-y
39 schema:sdDatePublished 2019-04-11T08:36
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N030c941cb2464ea98e874f08d5c05327
42 schema:url https://link.springer.com/10.1186%2Fs40425-018-0475-y
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N016bca55ddc541f19f1f584521fa8acf rdf:first sg:person.0670500635.41
47 rdf:rest Ne318d6a609ed4aa8a712b0c79f273bbd
48 N030c941cb2464ea98e874f08d5c05327 schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 N194c0ac09f49416f9d5258069f2ccac2 schema:issueNumber 1
51 rdf:type schema:PublicationIssue
52 N1e98ee9082fd4b77a7440bc66e12a13d rdf:first sg:person.01006050445.56
53 rdf:rest N83c21d6107eb44ca89b161a165558399
54 N249f80e26db544d1ad2205c483013c30 schema:volumeNumber 7
55 rdf:type schema:PublicationVolume
56 N2b6ab171281c431a90cc35a18585c579 schema:name doi
57 schema:value 10.1186/s40425-018-0475-y
58 rdf:type schema:PropertyValue
59 N38aff7d9536f4cbc9f11bbde3d7ea33e schema:name pubmed_id
60 schema:value 30621779
61 rdf:type schema:PropertyValue
62 N45bd29dc183e41c49d31ba4453591b8b rdf:first N53f9e102617a4bcc92196d754422ef0e
63 rdf:rest N1e98ee9082fd4b77a7440bc66e12a13d
64 N4878f90b5e01444d93c57767190079de rdf:first sg:person.01165122667.40
65 rdf:rest Nfb2c47dbcfb04f7face1bde499e84aea
66 N521c8c77ec2a4b3190b6c5e3b284b058 schema:name readcube_id
67 schema:value aad389d22b6c4a07def7164f5be81980c4a197d4ff07dc25d6fcd007ea71e5cf
68 rdf:type schema:PropertyValue
69 N53f9e102617a4bcc92196d754422ef0e schema:affiliation https://www.grid.ac/institutes/grid.410711.2
70 schema:familyName Ziemer
71 schema:givenName Carolyn M.
72 rdf:type schema:Person
73 N601c37eda51540279458f74ab391ea8b schema:affiliation Nab7ba603904d46dfaf951b486e6584a2
74 schema:familyName Landman
75 schema:givenName Paula
76 rdf:type schema:Person
77 N83c21d6107eb44ca89b161a165558399 rdf:first N601c37eda51540279458f74ab391ea8b
78 rdf:rest N016bca55ddc541f19f1f584521fa8acf
79 N8dc1fbf03bac40708d68b9f906a17552 schema:name dimensions_id
80 schema:value pub.1111265578
81 rdf:type schema:PropertyValue
82 Na3ceb708bf6b49228afb509a882bb812 schema:name nlm_unique_id
83 schema:value 101620585
84 rdf:type schema:PropertyValue
85 Nab7ba603904d46dfaf951b486e6584a2 schema:name UNC Health Care, The University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA
86 rdf:type schema:Organization
87 Ne318d6a609ed4aa8a712b0c79f273bbd rdf:first sg:person.011104144247.43
88 rdf:rest rdf:nil
89 Nfb2c47dbcfb04f7face1bde499e84aea rdf:first sg:person.016642556614.97
90 rdf:rest N45bd29dc183e41c49d31ba4453591b8b
91 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
92 schema:name Medical and Health Sciences
93 rdf:type schema:DefinedTerm
94 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
95 schema:name Oncology and Carcinogenesis
96 rdf:type schema:DefinedTerm
97 sg:journal.1049249 schema:issn 2051-1426
98 schema:name Journal for ImmunoTherapy of Cancer
99 rdf:type schema:Periodical
100 sg:person.01006050445.56 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
101 schema:familyName Whang
102 schema:givenName Young E.
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006050445.56
104 rdf:type schema:Person
105 sg:person.011104144247.43 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
106 schema:familyName Collichio
107 schema:givenName Frances A.
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104144247.43
109 rdf:type schema:Person
110 sg:person.01165122667.40 schema:affiliation https://www.grid.ac/institutes/grid.255364.3
111 schema:familyName Naqash
112 schema:givenName Abdul Rafeh
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165122667.40
114 rdf:type schema:Person
115 sg:person.016642556614.97 schema:affiliation https://www.grid.ac/institutes/grid.410711.2
116 schema:familyName File
117 schema:givenName Danielle M.
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016642556614.97
119 rdf:type schema:Person
120 sg:person.0670500635.41 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
121 schema:familyName Googe
122 schema:givenName Paul B.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670500635.41
124 rdf:type schema:Person
125 sg:pub.10.1007/s00277-017-2993-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1085391334
126 https://doi.org/10.1007/s00277-017-2993-y
127 rdf:type schema:CreativeWork
128 sg:pub.10.1038/nrclinonc.2017.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084511385
129 https://doi.org/10.1038/nrclinonc.2017.43
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1056/nejmc1114329 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014731818
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1080/14737140.2017.1341315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085978821
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1093/annonc/mdx187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085285234
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1093/annonc/mdx325 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086385919
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1093/jnci/djv414 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079221501
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1097/cmr.0000000000000472 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105411325
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1111/1346-8138.13489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031769697
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1111/j.1365-2133.2006.07704.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033804905
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1111/jdv.13892 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035467171
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1126/scitranslmed.aaa4691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043215332
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1158/2326-6066.cir-13-0092 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008089107
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1158/2326-6066.cir-13-0215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044941438
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1177/1758834015616934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077372
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1200/jco.2013.52.1377 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032160428
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1200/jco.2016.34.15_suppl.3014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106841551
160 rdf:type schema:CreativeWork
161 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
162 schema:name Department of Dermatology, Pathology and Laboratory Medicine, University of North Carolina School of Medicine, 250 Bell Tower Drive CB#7287, 27599, Chapel Hill, NC, USA
163 Department of Medicine, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.255364.3 schema:alternateName East Carolina University
166 schema:name Department of Medicine, Division of Hematology/Oncology, Vidant Cancer Center at East Carolina University, 600 Moye Blvd, 27834, Greenville, NC, USA
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.410711.2 schema:alternateName University of North Carolina System
169 schema:name Department of Dermatology, University of North Carolina, 27516, Chapel Hill, NC, USA
170 Department of Medicine, Division of Hematology/Oncology, University of North Carolina, 170 Manning Drive, 27599, Chapel Hill, NC, USA
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...